OA is associated with a reduction of the molecular weight and concentration of HA in the synovial fluid causing a worsening of its rheological properties and contributing to OA progression1
Hyalone® for TEMPORARY SYNOVIAL FLUID REPLACEMENT reducing pain symptoms and improving joint functionality2
Composition
Hyaluronic acid sodium salt (60mg/4mL) obtained by bacterial fermentation from a fraction of high molecular weight2
Available Presentation
Box containing 1 pre-filled syringe sealed in a blister2
Indications
Treatment of pain and improvement of joint functionality in patients affected by degenerative or mechanical arthropathy of the knee and hip joint2
Dosage & Administration
Treatment cycle:
1 injection2
Available PRESENTATION
Box containing 1 single dose.
Product portfolio
VISCOSUPPLEMENTATION
Medical Devices CE0459. Read the instructions for use carefully.
References:
1. Migliore A et al, J Rare Dis Res Treat. 2019;
2. HYALONE® Patient Information Leaflet